pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$EYPTEyePoint, Inc.

$EYPT5.4000-14.29%
Watertown, MA, USupdated 11h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 3: 1Marketed: 1
1Phase 31Marketed
Marketed
Dexycu
Ocular Inflammation
Phase 3
vorolanib
Wet (Neovascular / Exudative) Macular Degeneration

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 5, 2026
earnings
$EYPT5.4000-14.29%
16d ago
EyePoint, Inc. earnings
EyePoint, Inc.
→
view all catalysts →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 17, 26SELLRibeiro Ramiro· Chief Medical Officer2,437 sh @ $15.00−$37K↗
  • Mar 16, 26BUYDuker Jay S.· President and CEO1,500 sh @ $13.15$20K↗
  • Mar 4, 26SELLRibeiro Ramiro· Chief Medical Officer2,438 sh @ $17.87−$44K↗
routine RSU / option mechanics (6)
  • Apr 17, 26option exerciseRibeiro Ramiro · Chief Medical Officer2,437 sh
  • Apr 17, 26option exerciseRibeiro Ramiro · Chief Medical Officer2,437 sh
  • Mar 23, 26otherDuker Jay S. · President and CEO76,766 sh
  • Mar 23, 26otherDuker Jay S. · President and CEO76,766 sh
  • Mar 23, 26otherDuker Jay S. · President and CEO97,500 sh
  • Mar 23, 26otherDuker Jay S. · President and CEO97,500 sh
🐶 Hiring Signal
No open roles indexed yet — view EyePoint, Inc. jobs →

News

  • EyePoint’s bid to compete with Eylea falls flat
    EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT…
    endpoints · 3d ago
identifiers
ticker
$EYPT
SEC CIK
0001314102
country
US
source
sec_tickers
top tags
Diabetic Macular Edema1Ophthalmology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 39m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?